

RequestedStudies (1)									
Sponsor ID	Study ID	Is Updatable	Study Title	Principal Investigator	Sponsor Name	Data Contributor Name	IRB/Approver Name	Data Request ID	
200662	NCT02291231	FALSE	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-course 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Inhaled Corticosteroids	GlaxoSmithKline	GlaxoSmithKline	GlaxoSmithKline	The Independent Review Panel	10462	
111597	NCT01000360	FALSE	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects With Severe Uncontrolled Refractory Asthma	GlaxoSmithKline	GlaxoSmithKline	GlaxoSmithKline	The Independent Review Panel	10462	
111575	NCT01691030	FALSE	MEAT 15075: A Randomized, Double-blind, Placebo-Controlled, Parallel-group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Severe Day in Subjects With Severe Refractory Asthma	GlaxoSmithKline	GlaxoSmithKline	GlaxoSmithKline	The Independent Review Panel	10462	
201616	NCT02050297	FALSE	A Multi-center, Randomized, Double-blind, Placebo-Controlled, Parallel-group Study to Compare Concurrent Versus Combination of Long-Acting Muscarinic Antagonist Treatment in Patients With Severe Eosinophilic Asthma (201616)	GlaxoSmithKline	GlaxoSmithKline	GlaxoSmithKline	The Independent Review Panel	10462	
106076	NCT01084319	FALSE	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study to Evaluate the Efficacy and Safety of Intravenous GSK33772847 in Patients With Severe Asthma	GlaxoSmithKline	GlaxoSmithKline	GlaxoSmithKline	The Independent Review Panel	10462	
207972	NCT03303080	FALSE	A Double-Blind (Sponsor Open) Placebo-controlled, Stratified, Parallel-group Study to Evaluate the Efficacy and Safety of Repeat Doses of GSK33772847 in Participants With Moderate to Severe Asthma With Allergic Fungal	GlaxoSmithKline	GlaxoSmithKline	GlaxoSmithKline	The Independent Review Panel	10462	
205687	NCT02008379	FALSE	A Randomized, Double-blind, Parallel-group Pilot Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab as an Add-on to Maintenance Treatment in Adults With Severe Bimodal Nasal Polyps - 01949702	GlaxoSmithKline	GlaxoSmithKline	GlaxoSmithKline	The Independent Review Panel	10462	
207797	NCT02007724	FALSE	A Randomized, Double-blind, Parallel-group, Multicenter, Stratified Study Evaluating the Efficacy and Safety of Repeat Doses of GSK33772847 Compared With Placebo in Participants With Moderate Severe Asthma	GlaxoSmithKline	GlaxoSmithKline	GlaxoSmithKline	The Independent Review Panel	10462	
111588	NCT01691032	FALSE	MEAT 15088: A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Multi-course Study of the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory	GlaxoSmithKline	GlaxoSmithKline	GlaxoSmithKline	The Independent Review Panel	10462	
01602161	NCT02007774	FALSE	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of ONY1148 Administered Subcutaneously in Symptomatic Subjects With Severe	Centoson, Inc.	Johnson & Johnson	Yale Project		10462	
SDY1095	NCT02026266	FALSE	Endotracheal Undersling Asthma Exacerbations Prevention and Persistence With Inhaled-Based Therapy: A Systems Approach Phase 2 (ECAC-26)		National Institute of Allergy and Infectious Diseases (NIAID)	ImmPort (a data-sharing platform funded by the National Institutes of Health)		10462	
SDY211	NCT02077347	FALSE	Intra-City Anti-IgE Therapy for Asthma (ICAC-06)		National Institute of Allergy and Infectious Diseases (NIAID)	ImmPort (a data-sharing platform funded by the National Institutes of Health)		10462	
SDY1028	NCT01430340	FALSE	Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (ECAC-20)		National Institute of Allergy and Infectious Diseases (NIAID)	ImmPort (a data-sharing platform funded by the National Institutes of Health)		10462	